• Discovering & developing proprietary prodrugs

    Our products have improved properties over approved drugs and address unmet medical needs in large, established markets.

  • Creating a diverse pipeline of prodrug therapeutics

    We employ our LAT™ (Ligand Activated Therapy) technology to improve the attributes of approved drugs.

  • Decades of experience in devising elegant solutions

    KemPharm® continues to implement its LAT™ technology to create prodrugs that are new molecules by chemically attaching ligand(s) to the parent drug.

Our Value Proposition

KemPharm® believes that its LAT™ technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

Learn More

KemPharm’s pipeline consists of multiple programs targeting opportunities in ADHD, pain, and CNS indications.

We employ our LAT™ (Ligand Activated Therapy) technology to improve the attributes of approved drugs.

Learn more about LAT™

March 2, 2020

Featured Publication

KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD

If approved, KemPharm believes that KP415 may address several unmet needs, including earlier onset of action and longer duration of therapeutic effect vs. other available methylphenidate products   Celebration, FL – March 2, 2020 – KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of […]

keep reading

KemPharm® Company Overview
KemPharm® Company Culture
  • KemPharm Submits KP415 NDA to the FDA for the...

  • KemPharm Reports Fourth Quarter and Full-Year...

  • Nasdaq Grants KemPharm’s Request for Extens...